London, UK, 5 MARCH 2024
30 Technology is excited to announce that we have successfully completed the final dosing for all participants enrolled in our Tuberculosis study based in South Africa. This marks a crucial step forward in our commitment to addressing TB, a major public health concern. Throughout the trial, we have worked closely with the team at TASK, patients, and local communities to ensure the highest standards of care and scientific rigor.
With the final dosing now concluded, our team will shift its focus to monitoring and evaluating the outcomes. Data collection and analysis are underway, and we anticipate having top-line results in Q3 2024. These findings will provide valuable insights into the potential of our treatment to improve TB care.